Regencell Bioscience Holdings Ltd is a bioscience company that focuses on research, development and commercialization of traditional Chinese medicine (TCM) for the treatment of neurocognitive disorders and degeneration, specifically attention deficit and hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). The Company launches three liquid based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
09/11/26	$5.625	+6.74%	191,588
06/11/26	$5.270	0.00%	207,844
05/11/26	$5.270	-2.77%	179,750
04/11/26	$5.420	-11.87%	276,696
03/11/26	$6.150	-2.23%	94,912

Delayed Quote Nasdaq

More quotes

Market Closed - Nasdaq 01:00:00 10/11/2026 +04			5-day change	1st Jan Change
5.625 ^USD	+6.74%		-10.57%	-73.21%

10-08	Regencell Bioscience Holdings Limited Reports Earnings Results for the Full Year Ended June 30, 2026	CI
07-27	Certain Ordinary Shares of Regencell Bioscience Holdings Limited are subject to a Lock-Up Agreement Ending on 27-JUL-2026.	CI

Market Cap	2.79B 2.49B 2.29B 2.08B 3.94B 261B 4.04B 27.41B 10.92B 140B 10.47B 10.25B 441B	P/E 2025	-2,351x	P/E 2026	-257x
Enterprise Value	2.78B 2.48B 2.28B 2.07B 3.92B 260B 4.02B 27.27B 10.87B 139B 10.42B 10.19B 439B	EV / Sales 2025	-	EV / Sales 2026	-
Free-Float	11.45%	Yield 2025 *	-	Yield 2026	-

Markets		Quality
Nasdaq	RGC	Delayed
CBOE	RGC	Real-time

10-08	Regencell Bioscience Holdings Limited Reports Earnings Results for the Full Year Ended June 30, 2026	CI
07-27	Certain Ordinary Shares of Regencell Bioscience Holdings Limited are subject to a Lock-Up Agreement Ending on 27-JUL-2026.	CI
05-09	Regencell Bioscience Holdings Limited Reports Earnings Results for the Half Year Ended December 31, 2025	CI
01/11/25	Regencell Bioscience Holdings Limited Reports Earnings Results for the Full Year Ended June 30, 2025	CI
31/10/25	Regencell Bioscience Holdings Limited Auditor Raises 'Going Concern' Doubt	CI
22/09/25	Regencell Bioscience Holdings Limited(NasdaqCM:RGC) added to S&P Global BMI Index	CI
30/06/25	Regencell Bioscience Holdings Limited Reports Earnings Results for the Half Year Ended December 31, 2024	CI
30/06/25	Regencell Bioscience Holdings Limited Announces Board Changes, Effective June 30, 2025	CI
25/06/25	Top Premarket Gainers	MT
23/06/25	Top Premarket Decliners	MT
20/06/25	Top Premarket Decliners	MT
18/06/25	Top Premarket Decliners	MT
17/06/25	Top Premarket Gainers	MT

Regencell Bioscience Holdings Limited Stock

Stocks

RGC

KYG7487R1002

Biotechnology & Medical Research

Valuation: Regencell Bioscience Holdings Limited

Chart: Regencell Bioscience Holdings Limited

Latest news: Regencell Bioscience Holdings Limited

Analysts' recommendations: Regencell Bioscience Holdings Limited

Press Releases: Regencell Bioscience Holdings Limited

News in other languages: Regencell Bioscience Holdings Limited

Quotes and Performance

Price Extremes

Managers and Directors: Regencell Bioscience Holdings Limited

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

10-08	Regencell Bioscience : Annual Report for Fiscal Year Ending June 30, 2026 (Form 20-F)	PU
06-17	RGC SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Regencell Bioscience (RGC) Investors of Securities Class Action Lawsuit Deadline on June 23, 2026	NE
06-16	RGC Holzer & Holzer, LLC Reminds Investors of the June 23, 2026 Lead Plaintiff Deadline in the Regencell Bioscience Holdings Limited Securities Class Action	NE
06-15	RGC Faruqi & Faruqi, LLP Reminds Regencell Bioscience (RGC) Investors of Securities Class Action Lawsuit Deadline on June 23, 2026	NE
06-12	RGC SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Regencell Bioscience (RGC) Investors of Securities Class Action Lawsuit Deadline on June 23, 2026	NE

27/06/25	El milagro de las hierbas : esta acción sube un 20.000% en un año sin vender nada
18/02/22	La formule liquide expérimentale RGC-COV19TM de Regencell Bioscience a démontré son efficacité, chez ses patients recrutés, dans l'élimination des symptômes légers à modérés de la COVID-19 au cours d'une période de traitement de...
18/02/22	La formulazione liquida sperimentale RGC-COV19TM di Regencell Bioscience si dimostra efficace nell'eliminazione dei sintomi di COVID-19 da lievi a moderati nei pazienti arruolati nello studio di efficacia EARTH, in un periodo di trattamento di 6...
17/02/22	Flüssigprüfformel RGC-COV19TM von Regencell Bioscience zeigt Wirksamkeit bei den rekrutierten Patienten in der Wirksamkeitsstudie EARTH und behebt leichte bis mäßige COVID-19-Symptome innerhalb von 6 Tagen
17/02/22	Ensayo de eficacia EARTH: la fórmula líquida en investigación RGC-COV19TM de Regencell Bioscience demuestra eficacia en los pacientes inscritos al eliminar los síntomas leves o moderados de la COVID-19 en un período de tratamiento de seis días

1 day	+6.74%
1 week	-10.57%
Current month	-16.17%
1 month	-23.47%
3 months	+3.97%
6 months	-80.79%
Current year	-73.21%

1 week	5.05	6.51
1 month	5.05	11.3
Current year	4.51	69
1 year	4.51	69
3 years	0.08	83.6
5 years	0.08	83.6
10 years	0.08	83.6

Manager	Title	Age	Since
Yat-Gai Au CEO	Chief Executive Officer	54	01/01/2014
Wai Hong Chung COO	Chief Operating Officer	49	01/08/2021
Yat-Pui Au PRN	Corporate Officer/Principal	52	01/02/2023

Director	Title	Age	Since
Wai Hong Chung BRD	Director/Board Member	49	28/12/2023
Yee Wah Hui BRD	Director/Board Member	54	01/07/2021
Wing Yan Lo BRD	Director/Board Member	65	13/12/2021

Date	Insider	Type	Main position	Quantity	% Market Cap.
27/05/26	Yee Wah Hui	Issuer sale	Director	-19,000	0.0038%
27/05/26	Wing Yan Lo	Issuer sale	Director	-70,600	0.0143%
18/03/26	Yee Wah Hui	Other	Director	592,230	0.1198%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
REGENCELL BIOSCIENCE HOLDINGS LIMITED	+6.74%	-10.57%	-56.80%	+1,374.14%	2.79B
WUXI APPTEC CO., LTD.	+2.24%	+8.40%	+58.47%	+69.00%	68.22B
ARGENX SE	+0.87%	+9.20%	+15.59%	+89.61%	59.82B
LONZA GROUP AG	+0.06%	+1.41%	+23.86%	+97.67%	56.07B
BEONE MEDICINES AG	+2.55%	+15.52%	+30.43%	+120.17%	47.67B
IQVIA HOLDINGS INC.	+2.58%	+7.89%	+32.49%	+45.30%	45.95B
REVOLUTION MEDICINES, INC.	+4.09%	+6.37%	+228.06%	+899.75%	43.29B
CELLTRION, INC.	-0.47%	+9.38%	+27.53%	+52.40%	35.66B
GENMAB A/S	-0.22%	-1.40%	+95.52%	+70.32%	34.73B
INSMED INCORPORATED	+1.48%	+6.21%	-38.80%	+395.73%	25.47B
Average	+1.73%	+5.67%	+41.64%	+321.41%	42B
Weighted average by Cap.	+1.41%	+7.71%	+52.96%	+191.88%

	2025	2026
Net sales	-	-
Net income	-3.58M -3.2M -2.94M -2.67M -5.06M -336M -5.19M -35.22M -14.04M -180M -13.45M -13.17M -566M	-11.7M -10.45M -9.61M -8.72M -16.53M -1.1B -16.94M -115M -45.83M -587M -43.92M -42.98M -1.85B
Net Debt	-4.35M -3.89M -3.58M -3.24M -6.15M -408M -6.3M -42.77M -17.05M -218M -16.34M -15.99M -688M	-13.9M -12.4M -11.41M -10.36M -19.63M -1.3B -20.12M -137M -54.42M -697M -52.16M -51.04M -2.2B